- Home
- XFOR vs VALU Comparison
XFOR vs VALU Comparison
Compare XFOR & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XFOR | VALU |
|---|---|---|
| Founded | 2014 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 340.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XFOR | VALU |
|---|---|---|
| Price | $3.98 | $38.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | ★ 879.6K | 3.4K |
| Earning Date | 11-05-2025 | 12-15-2025 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.26 |
| Revenue | $33,979,000.00 | ★ $34,516,000.00 |
| Revenue This Year | $1,276.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.02 |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | $32.94 |
| 52 Week High | $26.83 | $54.30 |
Technical Indicators
Market Signals| Indicator | XFOR | VALU |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 53.50 |
| Support Level | $3.50 | $37.33 |
| Resistance Level | $4.56 | $39.55 |
| Average True Range (ATR) | 0.30 | 0.88 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 47.91 | 43.45 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.